{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T13:01:38Z","timestamp":1772802098815,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The effect of baseline resistance\u2010associated substitutions on the sustained virologic response at 12\u00a0weeks in chronic hepatitis C subjects has drawn considerable attention. However, it has been reported that the relationship between such substitutions and sustained virologic response at 12\u00a0weeks in chronic hepatitis C subjects is variable in different treatments. This meta\u2010analysis was performed to evaluate this relationship in subjects treated with glecaprevir\/pibrentasvir. A systematic literature search up to May 2020 was done, and 17 studies were identified with 6501 chronic hepatitis C subjects. They were reporting relationships between baseline resistance\u2010associated substitutions and sustained virologic response at 12\u00a0weeks in chronic hepatitis C subjects treated with glecaprevir\/pibrentasvir. The odds ratio (OR) with 95% confidence intervals (CIs) was calculated to evaluate the prognostic role of baseline resistance\u2010associated substitutions on the sustained virologic response at 12\u00a0weeks in chronic hepatitis C subjects treated with glecaprevir\/pibrentasvir using the dichotomous method with a random or fixed\u2010effect model. Lower sustained virologic response at 12\u00a0weeks post\u2010treatment in chronic hepatitis C subjects was significantly related to baseline resistance\u2010associated substitutions in overall genotypes (OR, 0.03; 95% CI, 0.15\u20100.61, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001), baseline NS5a resistance\u2010associated substitutions in genotype\u20101 (OR, 0.16; 95% CI, 0.04\u20100.57, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.005), baseline resistance\u2010associated substitutions in genotype\u20103 (OR, 0.14; 95% CI, 0.05\u20100.38, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001), and baseline NS5a resistance\u2010associated substitutions in genotype\u20103 (OR, 0.21; 95% CI, 0.09\u20100.49, <jats:italic>P<\/jats:italic>\u00a0&lt;\u00a0.001). Sustained virologic response at 12\u00a0weeks in chronic hepatitis C subjects was not significantly related to the baseline NS5a resistance\u2010associated substitutions (OR, 0.61; 95% CI, 0.17\u20102.22, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.45), and baseline resistance\u2010associated substitutions in genotype\u20101 (OR, 0.35; 95% CI, 0.12\u20101.088, <jats:italic>P<\/jats:italic>\u00a0=\u00a0.07). In conclusion, the impact of baseline resistance\u2010associated substitutions on the sustained virologic response at 12\u00a0weeks in chronic hepatitis C subjects treated with glecaprevir\/pibrentasvir may have a great prognostic effect, especially in genotype\u20103 as a tool to improve treatment prediction. Chronic hepatitis C subjects with baseline resistance\u2010associated substitutions may have an independent risk relationship with poor treatment outcomes. This relationship forces us to recommend testing prior to treatment selection to avoid any possible treatment failure.<\/jats:p>","DOI":"10.1111\/jvh.13409","type":"journal-article","created":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T01:13:08Z","timestamp":1600823588000},"page":"177-185","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of baseline resistance\u2010associated substitutions on the efficiency of glecaprevir\/pibrentasvir in chronic hepatitis C subjects: A meta\u2010analysis"],"prefix":"10.1111","volume":"28","author":[{"given":"Yonggui","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastroenterology China\u2010Japan Union Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuefeng","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology China\u2010Japan Union Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuyang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology China\u2010Japan Union Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8614-224X","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology China\u2010Japan Union Hospital of Jilin University  Changchun China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0145-y"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2018.01.004"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27259"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/1574887114666190306154650"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.007"},{"key":"e_1_2_10_8_1","unstructured":"Diseases A.A.f.t.S.o.L. and I.D.S.o. America Recommendations for Testing.Managing and treating hepatitis C.http:\/\/www.hcvguidelines.org. Accessed May 1 2018."},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02217-17"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.06.002"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.15.2008"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000388"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00009"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01569-7"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01249-18"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.007"},{"key":"e_1_2_10_19_1","unstructured":"OsawaM ImamuraM TeraokaY et al.Real\u2010world efficacy of glecaprevir plus pibrentasvir for patients with HCV with or without prior daa therapies: evaluation by deep sequencing for HCV strains with NS5A\u2010RAS. in Hepatology. 2018. WILEY 111 RIVER ST HOBOKEN 07030\u20135774 NJ USA."},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.07.020"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30046"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29671"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702417"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30496-6"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704053"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29081"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.09.027"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30341-8"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29510"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1391-5"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-017-1396-0"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15633"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01249-18"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12870"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.07.005"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2017.06.009"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.09.011"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02558-16"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512612"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.01.031"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13409","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13409","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T07:58:32Z","timestamp":1693209512000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1111\/jvh.13409"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13409","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,13]]},"assertion":[{"value":"2020-07-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}